Fulcrum Therapeutics, INC.

identify high-value, de-risked targets at speed and scale for rare genetic diseases

Based in MA

🤖

AI Overview

With $320K in lobbying spend across 11 quarterly filings, Fulcrum Therapeutics, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2022 to 2024.

$320K
Total Spend
3
Years Active
1
Firms Hired
5
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2022$50K
2023$120K
2024$150K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy

  • Any legislation regarding rare disease treatment
  • H.R. 6216/S. 3389 - Sickle Cell Disease Comprehensive Care Act (117th Congress) H.R. 8855/S. 4866, the Sickle Cell Disease Treatment Centers Act of 2022 (117th Congress) H.R.5376 - Inflation Reduction
  • Senate HELP Minority- FDA Modernization
  • FDA Matters

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.